UNSPSC 51203301: Lenalidomide

This classification denotes a biological response modifier with the molecular formula C13H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) F0P408N6V4, chemically known as 2,6-piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2h-isoindol-2-yl)- but more generally known as lenalidomide, which bears US NIH Compound Identifier 216326. European Medicines Agency schedules Lenalidomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25389.

UNSPSC 51203301 Lenalidomide, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The code nominally describes a specific prescription medication (lenalidomide, a thalidomide analog used in multiple myeloma and related cancers), but the four recent opportunities posted under this code soliciting pharmacy supplies span naloxone kits and drug deactivation systems, first-aid medical consumables for fire rescue, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and a request for information on direct-to-manufacturer prescription programs. None of these solicitations name or require lenalidomide specifically. The issuing bodies include Seminole County, Florida (health department procurement), the City of Tampa (fire department), the Texas Health and Human Services Commission (HHS pharmacy benefit program), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving state and local government facilities across multiple states including Oregon. The geographic spread spans Florida, Texas, and the Upper Midwest, with MMCAP's multistate cooperative model extending reach across participating jurisdictions. Activity appears intermittent rather than concentrated—the source shows no repeat buyers sourcing under this code, and the mismatch between the code's nominal pharmaceutical scope and the actual work being bought suggests the tagging is either an error or reflects a state or local procurement office's broad interpretation of pharmaceutical supply categories.

The representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (IFB 60459723LAS, due July 26, 2023), the City of Tampa's sealed-bid solicitation for medical and first-aid supplies for the Fire Department Rescue Division (Bid 26P00145, due March 13, 2026, with an estimated contract amount of $700,000 and a 5% SLBE bid discount), MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (RFP S1070000015802, due March 26, 2026), and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (RFI HHS0017013, due April 3, 2026). Vendors pursuing work under this code should verify with issuing offices that their specific products or services align with actual solicitation scope before bidding, as the commodity classification appears inconsistently applied across these recent postings.